Čarapić, Marija

Link to this page

Authority KeyName Variants
e8948652-6752-434b-8463-195575fb5f8b
  • Čarapić, Marija (8)
Projects

Author's Bibliography

Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities

Dokmanović, Jelena; Kasagić-Vujanović, Irena; Gagić, Žarko; Nikolić, Katarina; Čarapić, Marija; Agbaba, Danica

(Akademiai Kiado ZRt., 2023)

TY  - JOUR
AU  - Dokmanović, Jelena
AU  - Kasagić-Vujanović, Irena
AU  - Gagić, Žarko
AU  - Nikolić, Katarina
AU  - Čarapić, Marija
AU  - Agbaba, Danica
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4474
AB  - Using the Design of Experiments methodology (Response-Surface Methodology and Derringer's Desirability Function), a simple, fast and robust RP-HPLC method was developed for the analysis of enrofloxacin (EFC), its impurity A (fluoroquinolonic acid, FQ) and impurity B (ciprofloxacin, CPX). Gradient elution of samples was performed on a Zorbax Eclipse XDB C18 column (150 × 4.6 mm, 3.5 μm) with a mobile phase consisting of 32 mM phosphate buffer pH 3.5-methanol (0 min-19.6% methanol; 15.5 min-19.6% methanol; 29.5 min-80% methanol; 30 min-19.6% methanol; 35 min-19.6% methanol), delivered at a flow rate of 1.5 mL min-1, wavelength of detection 278 nm (for EFX and CFX) and 265 nm for FQ. A good linear response was achieved in the range 15-35 μg mL-1 (EFX) and LOQ-150% for impurities (CFX and FQ). Other validation parameters were also tested: precision, accuracy, sensitivity and robustness. The developed method was shown to be simple, practical and suitable for the analysis of EFC and its impurities (CPX, FQ) in veterinary drugs.
PB  - Akademiai Kiado ZRt.
T2  - Acta Chromatographica
T1  - Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities
DO  - 10.1556/1326.2022.01111
ER  - 
@article{
author = "Dokmanović, Jelena and Kasagić-Vujanović, Irena and Gagić, Žarko and Nikolić, Katarina and Čarapić, Marija and Agbaba, Danica",
year = "2023",
abstract = "Using the Design of Experiments methodology (Response-Surface Methodology and Derringer's Desirability Function), a simple, fast and robust RP-HPLC method was developed for the analysis of enrofloxacin (EFC), its impurity A (fluoroquinolonic acid, FQ) and impurity B (ciprofloxacin, CPX). Gradient elution of samples was performed on a Zorbax Eclipse XDB C18 column (150 × 4.6 mm, 3.5 μm) with a mobile phase consisting of 32 mM phosphate buffer pH 3.5-methanol (0 min-19.6% methanol; 15.5 min-19.6% methanol; 29.5 min-80% methanol; 30 min-19.6% methanol; 35 min-19.6% methanol), delivered at a flow rate of 1.5 mL min-1, wavelength of detection 278 nm (for EFX and CFX) and 265 nm for FQ. A good linear response was achieved in the range 15-35 μg mL-1 (EFX) and LOQ-150% for impurities (CFX and FQ). Other validation parameters were also tested: precision, accuracy, sensitivity and robustness. The developed method was shown to be simple, practical and suitable for the analysis of EFC and its impurities (CPX, FQ) in veterinary drugs.",
publisher = "Akademiai Kiado ZRt.",
journal = "Acta Chromatographica",
title = "Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities",
doi = "10.1556/1326.2022.01111"
}
Dokmanović, J., Kasagić-Vujanović, I., Gagić, Ž., Nikolić, K., Čarapić, M.,& Agbaba, D.. (2023). Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities. in Acta Chromatographica
Akademiai Kiado ZRt...
https://doi.org/10.1556/1326.2022.01111
Dokmanović J, Kasagić-Vujanović I, Gagić Ž, Nikolić K, Čarapić M, Agbaba D. Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities. in Acta Chromatographica. 2023;.
doi:10.1556/1326.2022.01111 .
Dokmanović, Jelena, Kasagić-Vujanović, Irena, Gagić, Žarko, Nikolić, Katarina, Čarapić, Marija, Agbaba, Danica, "Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities" in Acta Chromatographica (2023),
https://doi.org/10.1556/1326.2022.01111 . .

Characterization of unknown degradant of ziprasidone with NMR spetroscopy

Čarapić, Marija; Petković, Miloš; Marković, Bojan; Popović-Nikolić, Marija; Agbaba, Danica; Nikolić, Katarina

(Society of Physical Chemists of Serbia, 2022)

TY  - CONF
AU  - Čarapić, Marija
AU  - Petković, Miloš
AU  - Marković, Bojan
AU  - Popović-Nikolić, Marija
AU  - Agbaba, Danica
AU  - Nikolić, Katarina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4684
AB  - Ziprasidone (ZIP) is the second generation antipsychotic drug with unique G-protein-coupled
(GPCR) receptor binding profile. It is a highly lipophilic and unstable compound. Our group
developed and validated the single liquid chromatographic (LC) system for simultaneous
determination of ZIP and its five main impurities (IMPs) and we modelled the Quantitative
Structure Retention Relationship (QSRR) of the additional ten compounds including unknown
detected degradant. One of two proposed structures were confirmed by UPLC-MS/MS study. The
further characterisation of unknown degradant was performed with NMR studies as un versatile
tool for characterisation of each compound and it is presented. Through several experiments which consists of investigation of chemical shitfs in NMR spectra of ZIP degradation products the
structure of unknown degradant was proposed and confirmed as in previous experiments.
PB  - Society of Physical Chemists of Serbia
C3  - PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings)
T1  - Characterization of unknown degradant of ziprasidone with NMR spetroscopy
VL  - II
SP  - 601
EP  - 604
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4684
ER  - 
@conference{
author = "Čarapić, Marija and Petković, Miloš and Marković, Bojan and Popović-Nikolić, Marija and Agbaba, Danica and Nikolić, Katarina",
year = "2022",
abstract = "Ziprasidone (ZIP) is the second generation antipsychotic drug with unique G-protein-coupled
(GPCR) receptor binding profile. It is a highly lipophilic and unstable compound. Our group
developed and validated the single liquid chromatographic (LC) system for simultaneous
determination of ZIP and its five main impurities (IMPs) and we modelled the Quantitative
Structure Retention Relationship (QSRR) of the additional ten compounds including unknown
detected degradant. One of two proposed structures were confirmed by UPLC-MS/MS study. The
further characterisation of unknown degradant was performed with NMR studies as un versatile
tool for characterisation of each compound and it is presented. Through several experiments which consists of investigation of chemical shitfs in NMR spectra of ZIP degradation products the
structure of unknown degradant was proposed and confirmed as in previous experiments.",
publisher = "Society of Physical Chemists of Serbia",
journal = "PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings)",
title = "Characterization of unknown degradant of ziprasidone with NMR spetroscopy",
volume = "II",
pages = "601-604",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4684"
}
Čarapić, M., Petković, M., Marković, B., Popović-Nikolić, M., Agbaba, D.,& Nikolić, K.. (2022). Characterization of unknown degradant of ziprasidone with NMR spetroscopy. in PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings)
Society of Physical Chemists of Serbia., II, 601-604.
https://hdl.handle.net/21.15107/rcub_farfar_4684
Čarapić M, Petković M, Marković B, Popović-Nikolić M, Agbaba D, Nikolić K. Characterization of unknown degradant of ziprasidone with NMR spetroscopy. in PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings). 2022;II:601-604.
https://hdl.handle.net/21.15107/rcub_farfar_4684 .
Čarapić, Marija, Petković, Miloš, Marković, Bojan, Popović-Nikolić, Marija, Agbaba, Danica, Nikolić, Katarina, "Characterization of unknown degradant of ziprasidone with NMR spetroscopy" in PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings), II (2022):601-604,
https://hdl.handle.net/21.15107/rcub_farfar_4684 .

Characterisation of novel impurity of ziprasidone with NMR spectroscopy and UPLC-MS/MS

Čarapić, Marija; Marković, Bojan; Petković, Miloš; Nikolić, Katarina; Agbaba, Danica

(European Research Network on Signal Transduction CA18133, 2022)

TY  - CONF
AU  - Čarapić, Marija
AU  - Marković, Bojan
AU  - Petković, Miloš
AU  - Nikolić, Katarina
AU  - Agbaba, Danica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4741
PB  - European Research Network on Signal Transduction CA18133
C3  - 2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event
T1  - Characterisation of novel impurity of ziprasidone with NMR spectroscopy and UPLC-MS/MS
SP  - 74
EP  - 74
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4741
ER  - 
@conference{
author = "Čarapić, Marija and Marković, Bojan and Petković, Miloš and Nikolić, Katarina and Agbaba, Danica",
year = "2022",
publisher = "European Research Network on Signal Transduction CA18133",
journal = "2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event",
title = "Characterisation of novel impurity of ziprasidone with NMR spectroscopy and UPLC-MS/MS",
pages = "74-74",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4741"
}
Čarapić, M., Marković, B., Petković, M., Nikolić, K.,& Agbaba, D.. (2022). Characterisation of novel impurity of ziprasidone with NMR spectroscopy and UPLC-MS/MS. in 2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event
European Research Network on Signal Transduction CA18133., 74-74.
https://hdl.handle.net/21.15107/rcub_farfar_4741
Čarapić M, Marković B, Petković M, Nikolić K, Agbaba D. Characterisation of novel impurity of ziprasidone with NMR spectroscopy and UPLC-MS/MS. in 2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event. 2022;:74-74.
https://hdl.handle.net/21.15107/rcub_farfar_4741 .
Čarapić, Marija, Marković, Bojan, Petković, Miloš, Nikolić, Katarina, Agbaba, Danica, "Characterisation of novel impurity of ziprasidone with NMR spectroscopy and UPLC-MS/MS" in 2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event (2022):74-74,
https://hdl.handle.net/21.15107/rcub_farfar_4741 .

The ANN-QSRR modeling of chromatographic properties of ziprasidone and its impurities

Čarapić, Marija; Nikolić, Katarina; Agbaba, Danica

(European Research Network on Signal Transduction CA18133, 2022)

TY  - CONF
AU  - Čarapić, Marija
AU  - Nikolić, Katarina
AU  - Agbaba, Danica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4740
PB  - European Research Network on Signal Transduction CA18133
C3  - 2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event
T1  - The ANN-QSRR modeling of chromatographic properties of ziprasidone and its impurities
SP  - 48
EP  - 48
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4740
ER  - 
@conference{
author = "Čarapić, Marija and Nikolić, Katarina and Agbaba, Danica",
year = "2022",
publisher = "European Research Network on Signal Transduction CA18133",
journal = "2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event",
title = "The ANN-QSRR modeling of chromatographic properties of ziprasidone and its impurities",
pages = "48-48",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4740"
}
Čarapić, M., Nikolić, K.,& Agbaba, D.. (2022). The ANN-QSRR modeling of chromatographic properties of ziprasidone and its impurities. in 2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event
European Research Network on Signal Transduction CA18133., 48-48.
https://hdl.handle.net/21.15107/rcub_farfar_4740
Čarapić M, Nikolić K, Agbaba D. The ANN-QSRR modeling of chromatographic properties of ziprasidone and its impurities. in 2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event. 2022;:48-48.
https://hdl.handle.net/21.15107/rcub_farfar_4740 .
Čarapić, Marija, Nikolić, Katarina, Agbaba, Danica, "The ANN-QSRR modeling of chromatographic properties of ziprasidone and its impurities" in 2nd Transatlantic ECI GPCR Symposium - Early Career Investigators – July 6-7, 2022, Online event (2022):48-48,
https://hdl.handle.net/21.15107/rcub_farfar_4740 .

Investigation of retention characteristics and an unknown degradant of ziprasidone, antipsychotic with unique profile binding for GPCRs receptor

Čarapić, Marija; Nikolić, Katarina; Agbaba, Danica

(European Research Network on Signal Transduction CA18133, 2022)

TY  - CONF
AU  - Čarapić, Marija
AU  - Nikolić, Katarina
AU  - Agbaba, Danica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4736
PB  - European Research Network on Signal Transduction CA18133
C3  - 6th ERNEST Meeting, Building a Comprehensive Map of GPCR Signal Transduction, 28-31 March, 2022.
T1  - Investigation of retention characteristics and an unknown degradant of ziprasidone, antipsychotic with unique profile binding for GPCRs receptor
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4736
ER  - 
@conference{
author = "Čarapić, Marija and Nikolić, Katarina and Agbaba, Danica",
year = "2022",
publisher = "European Research Network on Signal Transduction CA18133",
journal = "6th ERNEST Meeting, Building a Comprehensive Map of GPCR Signal Transduction, 28-31 March, 2022.",
title = "Investigation of retention characteristics and an unknown degradant of ziprasidone, antipsychotic with unique profile binding for GPCRs receptor",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4736"
}
Čarapić, M., Nikolić, K.,& Agbaba, D.. (2022). Investigation of retention characteristics and an unknown degradant of ziprasidone, antipsychotic with unique profile binding for GPCRs receptor. in 6th ERNEST Meeting, Building a Comprehensive Map of GPCR Signal Transduction, 28-31 March, 2022.
European Research Network on Signal Transduction CA18133..
https://hdl.handle.net/21.15107/rcub_farfar_4736
Čarapić M, Nikolić K, Agbaba D. Investigation of retention characteristics and an unknown degradant of ziprasidone, antipsychotic with unique profile binding for GPCRs receptor. in 6th ERNEST Meeting, Building a Comprehensive Map of GPCR Signal Transduction, 28-31 March, 2022.. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_4736 .
Čarapić, Marija, Nikolić, Katarina, Agbaba, Danica, "Investigation of retention characteristics and an unknown degradant of ziprasidone, antipsychotic with unique profile binding for GPCRs receptor" in 6th ERNEST Meeting, Building a Comprehensive Map of GPCR Signal Transduction, 28-31 March, 2022. (2022),
https://hdl.handle.net/21.15107/rcub_farfar_4736 .

New regulatory requirements in revision of ICH Q2(R2) guideline on the validation of analytical procedures

Čarapić, Marija; Vojvodić, Ljiljana; Nikolić, Katarina; Agbaba, Danica

(Savez farmaceutskih udruženja Srbije (SFUS), 2022)

TY  - CONF
AU  - Čarapić, Marija
AU  - Vojvodić, Ljiljana
AU  - Nikolić, Katarina
AU  - Agbaba, Danica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4601
AB  - Guideline ICHQ2(R1) (June 1995) provides general recommendations about
performing the validation of standard analytical procedures (HPLC/TLC/GC) used for testing
the active substance (AS)/finished product in order to show that the method is suitable for
its intended use (ensuring the quality of the medicine). The development of a new guideline
ICHQ14 Analytical procedure development is underway, which consequently led to a revision
of the guideline ICHQ2 in the R2 version (comments until July 2022). The aim of this paper is
to present an overview of new regulatory elements that should be considered during the
validation of the analytical procedure. In relation to R1, ICHQ2(R2) provides
recommendations for performing/evaluating various validation tests taking into account the
specificity of each analytical procedure. Validation principles covering the use of
spectroscopic/spectrometric data (e.g. NIR/Raman/NMR/MS) are described, some of which
often require multivariate statistical analyzes. Guideline-R1 referred to the most frequently
tested specification/process parameters (identification, testing of impurities
quantitatively/limit test, assay (1,2)). R2 describes the methodology for performing
validation for testing: elemental impurities (ICP-OES/ICP-MS), genotoxic impurities (LC/MS),
dissolution testing (HPLC), particle size determination, core tablet assay by NIR (e.g. in
continuous manufacturing), quantitative 1 H-NMR for the assay of AS. The validation
methodology used in specific tests for biological/biotechnological drugs for biological assay
(ELISA, SPR) and impurity testing-quantitative PCR, is also described. If scientifically
justified, relevant data from development studies (ICHQ14) can be used instead of validation
or the validation process can be abbreviated when an already established platform analytical
procedure is used for a new purpose.
AB  - Smernica ICHQ2(R1) (jun 1995.) daje opšte preporuke o načinu izvođenja validacije
standardnih analitičkih metoda (HPLC/TLC/GC) koje se koriste za ispitivanje aktivne
supstance (AS) i gotovog proizvoda što ima za cilj da pokaže da je metoda pogodna za
predviđenu svrhu (obezbeđenje kvaliteta leka). U toku je razvoj nove smernice ICHQ14 o
razvoju analitičkih metoda što je posledično dovelo do revizije smernice ICHQ2 u verziju R2
(na javnoj raspravi do jula 2022.). Cilj ovog rada je da se prikaže pregled novih regulatornih
elemenata koje treba razmatrati u toku validacije analitičke procedure. U odnosu na R1,
ICHQ2(R2) daje preporuke za izvođenje i procenu različitih testova validacije uzimajući u
obzir specifičnost svake analitičke procedure. Biće opisani postupci validacije koji pokrivaju
upotrebu spektroskopskih/spektrometrijskih podataka (npr. NIR, Raman, NMR ili MS) od
kojih neki često zahtevaju multivarijantne statističke analize. Smernica-R1 se odnosila na
najčešće ispitivane specifikacijske/procesne parametre (identifikacija, ispitivanje nečistoća
kvantitativno/limit test, sadržaj AS (1,2)). Verzija R2 opisuje metodologiju izvođenja
validacije za ispitivanje elelmentalnih nečistoća (ICP-OES/ICP-MS), ispitivanje genotoksičnih
nečistoća - LC/MS, ispitivanja brzine oslobađanja aktivne supstance-HPLC, određivanje
veličine čestica, validacija NIR metode za ispitivanje sadržaja AS u tabletnom jezgru (npr. kod
kontinuirane proizvodnje), validacija H-NMR za određivanje sadržaja AS. Opisana je i
validaciona metodologija koja se primenjuje kod spefičnih testova za biološke/biotehnološke
lekove za određivanje sadržaja AS (ELISA, SPR) i ispitivanje nečistoća-PCR. Ako je to
naučno opravdano, odgovarajući podaci dobijeni iz razvojnih studija (ICHQ14)
mogu se koristiti umesto validacije ili postupak validacije može biti skraćen kada
se već utvrđena platforma analitičke procedure koristi u novu svrhu.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - New regulatory requirements in revision of ICH Q2(R2) guideline on the validation of analytical procedures
T1  - Novi regulatorni zahtevi u reviziji ICH Q2 smernice o validaciji analitičkih metoda
VL  - 72
IS  - 4 suplement
SP  - S538
EP  - S539
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4601
ER  - 
@conference{
author = "Čarapić, Marija and Vojvodić, Ljiljana and Nikolić, Katarina and Agbaba, Danica",
year = "2022",
abstract = "Guideline ICHQ2(R1) (June 1995) provides general recommendations about
performing the validation of standard analytical procedures (HPLC/TLC/GC) used for testing
the active substance (AS)/finished product in order to show that the method is suitable for
its intended use (ensuring the quality of the medicine). The development of a new guideline
ICHQ14 Analytical procedure development is underway, which consequently led to a revision
of the guideline ICHQ2 in the R2 version (comments until July 2022). The aim of this paper is
to present an overview of new regulatory elements that should be considered during the
validation of the analytical procedure. In relation to R1, ICHQ2(R2) provides
recommendations for performing/evaluating various validation tests taking into account the
specificity of each analytical procedure. Validation principles covering the use of
spectroscopic/spectrometric data (e.g. NIR/Raman/NMR/MS) are described, some of which
often require multivariate statistical analyzes. Guideline-R1 referred to the most frequently
tested specification/process parameters (identification, testing of impurities
quantitatively/limit test, assay (1,2)). R2 describes the methodology for performing
validation for testing: elemental impurities (ICP-OES/ICP-MS), genotoxic impurities (LC/MS),
dissolution testing (HPLC), particle size determination, core tablet assay by NIR (e.g. in
continuous manufacturing), quantitative 1 H-NMR for the assay of AS. The validation
methodology used in specific tests for biological/biotechnological drugs for biological assay
(ELISA, SPR) and impurity testing-quantitative PCR, is also described. If scientifically
justified, relevant data from development studies (ICHQ14) can be used instead of validation
or the validation process can be abbreviated when an already established platform analytical
procedure is used for a new purpose., Smernica ICHQ2(R1) (jun 1995.) daje opšte preporuke o načinu izvođenja validacije
standardnih analitičkih metoda (HPLC/TLC/GC) koje se koriste za ispitivanje aktivne
supstance (AS) i gotovog proizvoda što ima za cilj da pokaže da je metoda pogodna za
predviđenu svrhu (obezbeđenje kvaliteta leka). U toku je razvoj nove smernice ICHQ14 o
razvoju analitičkih metoda što je posledično dovelo do revizije smernice ICHQ2 u verziju R2
(na javnoj raspravi do jula 2022.). Cilj ovog rada je da se prikaže pregled novih regulatornih
elemenata koje treba razmatrati u toku validacije analitičke procedure. U odnosu na R1,
ICHQ2(R2) daje preporuke za izvođenje i procenu različitih testova validacije uzimajući u
obzir specifičnost svake analitičke procedure. Biće opisani postupci validacije koji pokrivaju
upotrebu spektroskopskih/spektrometrijskih podataka (npr. NIR, Raman, NMR ili MS) od
kojih neki često zahtevaju multivarijantne statističke analize. Smernica-R1 se odnosila na
najčešće ispitivane specifikacijske/procesne parametre (identifikacija, ispitivanje nečistoća
kvantitativno/limit test, sadržaj AS (1,2)). Verzija R2 opisuje metodologiju izvođenja
validacije za ispitivanje elelmentalnih nečistoća (ICP-OES/ICP-MS), ispitivanje genotoksičnih
nečistoća - LC/MS, ispitivanja brzine oslobađanja aktivne supstance-HPLC, određivanje
veličine čestica, validacija NIR metode za ispitivanje sadržaja AS u tabletnom jezgru (npr. kod
kontinuirane proizvodnje), validacija H-NMR za određivanje sadržaja AS. Opisana je i
validaciona metodologija koja se primenjuje kod spefičnih testova za biološke/biotehnološke
lekove za određivanje sadržaja AS (ELISA, SPR) i ispitivanje nečistoća-PCR. Ako je to
naučno opravdano, odgovarajući podaci dobijeni iz razvojnih studija (ICHQ14)
mogu se koristiti umesto validacije ili postupak validacije može biti skraćen kada
se već utvrđena platforma analitičke procedure koristi u novu svrhu.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "New regulatory requirements in revision of ICH Q2(R2) guideline on the validation of analytical procedures, Novi regulatorni zahtevi u reviziji ICH Q2 smernice o validaciji analitičkih metoda",
volume = "72",
number = "4 suplement",
pages = "S538-S539",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4601"
}
Čarapić, M., Vojvodić, L., Nikolić, K.,& Agbaba, D.. (2022). New regulatory requirements in revision of ICH Q2(R2) guideline on the validation of analytical procedures. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S538-S539.
https://hdl.handle.net/21.15107/rcub_farfar_4601
Čarapić M, Vojvodić L, Nikolić K, Agbaba D. New regulatory requirements in revision of ICH Q2(R2) guideline on the validation of analytical procedures. in Arhiv za farmaciju. 2022;72(4 suplement):S538-S539.
https://hdl.handle.net/21.15107/rcub_farfar_4601 .
Čarapić, Marija, Vojvodić, Ljiljana, Nikolić, Katarina, Agbaba, Danica, "New regulatory requirements in revision of ICH Q2(R2) guideline on the validation of analytical procedures" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S538-S539,
https://hdl.handle.net/21.15107/rcub_farfar_4601 .

Development and validation of UHPLC-MS/MS method for analysis of ziprasidone and its impurities

Čarapić, Marija; Marković, Bojan; Nikolić, Katarina; Agbaba, Danica

(Savez farmaceutskih udruženja Srbije (SFUS), 2022)

TY  - CONF
AU  - Čarapić, Marija
AU  - Marković, Bojan
AU  - Nikolić, Katarina
AU  - Agbaba, Danica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4600
AB  - Ziprasidone, bensiothiasol piperazynylindolone derivative is second generation
antipsychotic drug used for the treatment of schizophrenia and in acute maniac/mixed
episodes associated with bipolar disorder. It has unique G-protein coupled receptor binding
profile with relatively low propensity for weight gain (1). Recently, it became an official
active pharmaceutical ingredient in European Pharmacopoeia, where there are three official
chromatographic systems, one for the assay and two other for early-eluiting and late-eluting
impurities. Therefore, the purpose of this investigation was to develop and validate a fast,
highly sensitive UHPLC-MS/MS method for the analysis of ziprasidone and its five impurities,
significantly differing in polarity and pKa. Separation was performed using Thermo ACCELA
UHPLC system (Thermo Scientific, Waltham, MA, USA) equipped with triple quad Mass
Spectrometer Thermo TSQ Quantum Access Max (Thermo Scientific, Waltham, MA, USA)
with a heated electro-spray ionization interface. Satisfactory chromatographic separation
was achieved using a gradient elution with mobile phase A (10mM ammonium formate
buffer, pH 4.7) and mobile phase B (acetonitrile) on a Acquity UPLC BEH C18 (50×2.1 mm,
1.7 μm) column with mobile phase flow rate of 300 μL/min. Sample injection volume was 10
μL. The analysis runtime was 7 minutes. The method was validated according to the
International Conference of Harmonization (ICH) guidelines and validation included
parameters such as specificity, linearity, accuracy, precision, limit of quantification and limit
of detection. The proposed rapid and sensitive method is convenient and reliable for the
assay and purity control in raw materials and in dosage forms (2).
AB  - Ziprasidon, derivat benzizotiazol piperazinilindolona, je antipsihotik druge generacije
koji se koristi za lečenje šizofrenije, kod akutnih maničnih ili mešovitih epizoda povezanih sa
bipolarnim poremećajem. Ima jedinstveni profil vezivanja za G protein-spregnute receptore
(GPCR) i relativno retko neželjeno dejstvo povećanja telesne težine (1). Nedavno je
monografija dve soli ziprasidona postala oficinalna u Evropskoj farmakopeji u kojoj se
ispitivanje vrši pomoću tri hromatografska sistema: ispitivanje sadržaja i dva odvojena
sistema za više i manje polarne nečistoće. Svrha ovog istraživanja bila da se razvije i validira
brza i visoko osetljiva UHPLC-MS/MS metoda za istovremeno ispitivanje ziprasidona i
njegovih pet nečistoća, koje se značajno razlikuju po polarnosti i pKa. Hromatografska
analiza je vršena na Thermo ACCELA UHPLC sistemu koji je spregnut sa tripl kvadrupolskim
masenim analizatorom Thermo TSQ Quantum Access Max (Thermo Scientific, Valtham, MA,
USA) sa elektrosprej jonizacijom na povišenoj temperaturi (HESI) kao jonskim izvorom.
Zadovoljavajuće razdvajanje dobijeno je korišć enjem gradijentog eluiranja sa mobilnom
fazom A (10 mM amonijum-formijat, pH 4,7) i mobilnom fazom B (acetonitril) na Acquity
UPLC BEH 50×2,1 mm, 1,7 μm (Waters) stacionarnoj fazi na temperaturi od 30ºC i pri
protoku mobilne faze od 300 μL/min. Zapremina injektovanja ispitivanih rastvora bila je
10 μL. Trajanje analize je 7 minuta (2). Metoda je validirana u skladu sa ICH (International
Council for Harmonisation) smernicom i pokazana je specifičnost metode, linearnost,
tačnost, preciznost, limit kvantifikacije i limit detekcije. Potvrđeno je da se brza i osetljiva
UHPLC-MS/MS metoda može primeniti za ispitivanje ziprasidona i njegovih nečistoća u
aktivnoj supstanci i doziranim oblicima.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Development and validation of UHPLC-MS/MS method for analysis of ziprasidone and its impurities
T1  - Razvoj i validacija UHPLC‐MS/MS metode za ispitivanje ziprasidona i njegovih nečistoća
VL  - 72
IS  - 4 suplement
SP  - S536
EP  - S537
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4600
ER  - 
@conference{
author = "Čarapić, Marija and Marković, Bojan and Nikolić, Katarina and Agbaba, Danica",
year = "2022",
abstract = "Ziprasidone, bensiothiasol piperazynylindolone derivative is second generation
antipsychotic drug used for the treatment of schizophrenia and in acute maniac/mixed
episodes associated with bipolar disorder. It has unique G-protein coupled receptor binding
profile with relatively low propensity for weight gain (1). Recently, it became an official
active pharmaceutical ingredient in European Pharmacopoeia, where there are three official
chromatographic systems, one for the assay and two other for early-eluiting and late-eluting
impurities. Therefore, the purpose of this investigation was to develop and validate a fast,
highly sensitive UHPLC-MS/MS method for the analysis of ziprasidone and its five impurities,
significantly differing in polarity and pKa. Separation was performed using Thermo ACCELA
UHPLC system (Thermo Scientific, Waltham, MA, USA) equipped with triple quad Mass
Spectrometer Thermo TSQ Quantum Access Max (Thermo Scientific, Waltham, MA, USA)
with a heated electro-spray ionization interface. Satisfactory chromatographic separation
was achieved using a gradient elution with mobile phase A (10mM ammonium formate
buffer, pH 4.7) and mobile phase B (acetonitrile) on a Acquity UPLC BEH C18 (50×2.1 mm,
1.7 μm) column with mobile phase flow rate of 300 μL/min. Sample injection volume was 10
μL. The analysis runtime was 7 minutes. The method was validated according to the
International Conference of Harmonization (ICH) guidelines and validation included
parameters such as specificity, linearity, accuracy, precision, limit of quantification and limit
of detection. The proposed rapid and sensitive method is convenient and reliable for the
assay and purity control in raw materials and in dosage forms (2)., Ziprasidon, derivat benzizotiazol piperazinilindolona, je antipsihotik druge generacije
koji se koristi za lečenje šizofrenije, kod akutnih maničnih ili mešovitih epizoda povezanih sa
bipolarnim poremećajem. Ima jedinstveni profil vezivanja za G protein-spregnute receptore
(GPCR) i relativno retko neželjeno dejstvo povećanja telesne težine (1). Nedavno je
monografija dve soli ziprasidona postala oficinalna u Evropskoj farmakopeji u kojoj se
ispitivanje vrši pomoću tri hromatografska sistema: ispitivanje sadržaja i dva odvojena
sistema za više i manje polarne nečistoće. Svrha ovog istraživanja bila da se razvije i validira
brza i visoko osetljiva UHPLC-MS/MS metoda za istovremeno ispitivanje ziprasidona i
njegovih pet nečistoća, koje se značajno razlikuju po polarnosti i pKa. Hromatografska
analiza je vršena na Thermo ACCELA UHPLC sistemu koji je spregnut sa tripl kvadrupolskim
masenim analizatorom Thermo TSQ Quantum Access Max (Thermo Scientific, Valtham, MA,
USA) sa elektrosprej jonizacijom na povišenoj temperaturi (HESI) kao jonskim izvorom.
Zadovoljavajuće razdvajanje dobijeno je korišć enjem gradijentog eluiranja sa mobilnom
fazom A (10 mM amonijum-formijat, pH 4,7) i mobilnom fazom B (acetonitril) na Acquity
UPLC BEH 50×2,1 mm, 1,7 μm (Waters) stacionarnoj fazi na temperaturi od 30ºC i pri
protoku mobilne faze od 300 μL/min. Zapremina injektovanja ispitivanih rastvora bila je
10 μL. Trajanje analize je 7 minuta (2). Metoda je validirana u skladu sa ICH (International
Council for Harmonisation) smernicom i pokazana je specifičnost metode, linearnost,
tačnost, preciznost, limit kvantifikacije i limit detekcije. Potvrđeno je da se brza i osetljiva
UHPLC-MS/MS metoda može primeniti za ispitivanje ziprasidona i njegovih nečistoća u
aktivnoj supstanci i doziranim oblicima.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Development and validation of UHPLC-MS/MS method for analysis of ziprasidone and its impurities, Razvoj i validacija UHPLC‐MS/MS metode za ispitivanje ziprasidona i njegovih nečistoća",
volume = "72",
number = "4 suplement",
pages = "S536-S537",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4600"
}
Čarapić, M., Marković, B., Nikolić, K.,& Agbaba, D.. (2022). Development and validation of UHPLC-MS/MS method for analysis of ziprasidone and its impurities. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S536-S537.
https://hdl.handle.net/21.15107/rcub_farfar_4600
Čarapić M, Marković B, Nikolić K, Agbaba D. Development and validation of UHPLC-MS/MS method for analysis of ziprasidone and its impurities. in Arhiv za farmaciju. 2022;72(4 suplement):S536-S537.
https://hdl.handle.net/21.15107/rcub_farfar_4600 .
Čarapić, Marija, Marković, Bojan, Nikolić, Katarina, Agbaba, Danica, "Development and validation of UHPLC-MS/MS method for analysis of ziprasidone and its impurities" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S536-S537,
https://hdl.handle.net/21.15107/rcub_farfar_4600 .

Genotoxic impurities in medicinal products – regulatory requirements

Čarapić, Marija; Nikolić, Katarina; Agbaba, Danica

(Savez farmaceutskih udruženja Srbije (SFUS), 2022)

TY  - CONF
AU  - Čarapić, Marija
AU  - Nikolić, Katarina
AU  - Agbaba, Danica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4476
AB  - Most chemical syntheses use highly reactive molecules, which are often DNA-reactive
(mutagens). They may be present in the active substance (AS) or in the drug product as
genotoxic impurities (GI). The mechanism of action of most GIs is based on DNA modification
by direct binding (electrophilic - alkylating agents), insertion into the DNA chain
(topoisomerase inhibitors) and antimetabolites (purine/pyrimidine analogs). Structural
alerts (SA) for carcinogenic activity are defined as functional groups or substructures of
compounds associated with carcinogenic activity (1). SA indicates a chemical group that causes
toxic effects through one or several common mechanisms of action. GIs can bind directly to DNA
or after metabolic transformations (oxidation and reduction), thus the SA structure may indicate
the formation of several toxic metabolites. The risk assessment for the presence of GIs is a
mandatory part in the module 3 (AS/DP impurity profile) submitted in the marketing authorization
procedure, also in the approval of clinical trials. Guideline ICHM7(2) provides recommendations
for identification, categorization, qualification and control strategy of mutagenic impurities in
order to limit the potential carcinogenic risk. According to ICHM7, the classification (class 1-5) of
all impurities is performed on the basis of data on carcinogenicity and bacterial mutagenicity (BM)
from databases/scientific literature. If data are not available, computational toxicological
assessment (QSAR) is performed and BM is predicted with two independent models. If any of
model shows SA structures, a BM assay (Ames test) is performed. The high potent mutagenic
carcinogens (aflatoxins, nitrosamines, alkyl-azoxy compounds) referred to as “cohort of concern”.
AB  - U većini hemijskih sinteza se koriste veoma reaktivni molekuli koji su često i DNK –
reaktivni (mutageni). Oni mogu biti prisutni u aktivnoj supstanci (AS) ili gotovom proizvodu
(GP) kao genotoksične nečistoće (GN). Mehanizam dejstva većine GN se zasniva na
modifikaciji DNK i to direktnim vezivanjem (elektrofili - alkilujući agensi), umetanjem u
lanac DNK (inhibitori topoizomeraze) i antimetaboliti (purinski/pirimidinski analozi).
Upozoravajuće strukture (SA) za kancerogenu aktivnost se definišu kao funkcionalne grupe
ili delovi strukture jedinjenja koje su povezane sa kancerogenom aktivnošću (1). SA ukazuje
na hemijsku grupu jedinjenja koja izaziva toksične efekte kroz jedan ili nekoliko obično
zajedničkih mehanizama delovanja. GN mogu direktno da se vezuju za DNK ili nakon
metaboličkih transformacija (oksidacija i redukcija) pa SA struktura može da ukaže na
nastanak nekoliko toksičnih metabolita. Procena rizika na prisustvo GN u delu koji se odnosi
na profil nečistoća AS/GP je obavezan deo dokumentacije o kvalitetu leka koji se podnosi u
postupku registracije leka, kao i odobravanja kliničkih ispitivanja. U smernici ICHM7(2) su
date preporuke za identifikaciju, kategorizaciju, kvalifikaciju i kontrolnu strategiju
mutagenih nečistoća kako bi se ograničio potencijalni kancerogeni rizik. Prema ICHM7 se
vrši klasifikacija (klase 1-5) svih nečistoća na osnovu podataka o kancerogenosti i
bakterijskoj mutagenosti iz baza i naučne literature. Ako podaci nisu dostupni sprovodi se in
silico toksikološka procena (QSAR) i predviđa se bakterijska mutagenost sa dva nezavisna
modela. Ako jedan od modela pokaže SA strukture, radi se test povratne mutacije na
bakterijama (Ames test). Posebno se razmatraju visoko potentni mutageni kancerogeni
(aflatoksini, nitrozamini, alkil-azoksi jedinjenja).
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Genotoxic impurities in medicinal products – regulatory requirements
T1  - Genotoksične nečistoće u lekovima ‐ regulatorni zahtevi
VL  - 72
IS  - 4 suplement
SP  - S133
EP  - S134
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4476
ER  - 
@conference{
author = "Čarapić, Marija and Nikolić, Katarina and Agbaba, Danica",
year = "2022",
abstract = "Most chemical syntheses use highly reactive molecules, which are often DNA-reactive
(mutagens). They may be present in the active substance (AS) or in the drug product as
genotoxic impurities (GI). The mechanism of action of most GIs is based on DNA modification
by direct binding (electrophilic - alkylating agents), insertion into the DNA chain
(topoisomerase inhibitors) and antimetabolites (purine/pyrimidine analogs). Structural
alerts (SA) for carcinogenic activity are defined as functional groups or substructures of
compounds associated with carcinogenic activity (1). SA indicates a chemical group that causes
toxic effects through one or several common mechanisms of action. GIs can bind directly to DNA
or after metabolic transformations (oxidation and reduction), thus the SA structure may indicate
the formation of several toxic metabolites. The risk assessment for the presence of GIs is a
mandatory part in the module 3 (AS/DP impurity profile) submitted in the marketing authorization
procedure, also in the approval of clinical trials. Guideline ICHM7(2) provides recommendations
for identification, categorization, qualification and control strategy of mutagenic impurities in
order to limit the potential carcinogenic risk. According to ICHM7, the classification (class 1-5) of
all impurities is performed on the basis of data on carcinogenicity and bacterial mutagenicity (BM)
from databases/scientific literature. If data are not available, computational toxicological
assessment (QSAR) is performed and BM is predicted with two independent models. If any of
model shows SA structures, a BM assay (Ames test) is performed. The high potent mutagenic
carcinogens (aflatoxins, nitrosamines, alkyl-azoxy compounds) referred to as “cohort of concern”., U većini hemijskih sinteza se koriste veoma reaktivni molekuli koji su često i DNK –
reaktivni (mutageni). Oni mogu biti prisutni u aktivnoj supstanci (AS) ili gotovom proizvodu
(GP) kao genotoksične nečistoće (GN). Mehanizam dejstva većine GN se zasniva na
modifikaciji DNK i to direktnim vezivanjem (elektrofili - alkilujući agensi), umetanjem u
lanac DNK (inhibitori topoizomeraze) i antimetaboliti (purinski/pirimidinski analozi).
Upozoravajuće strukture (SA) za kancerogenu aktivnost se definišu kao funkcionalne grupe
ili delovi strukture jedinjenja koje su povezane sa kancerogenom aktivnošću (1). SA ukazuje
na hemijsku grupu jedinjenja koja izaziva toksične efekte kroz jedan ili nekoliko obično
zajedničkih mehanizama delovanja. GN mogu direktno da se vezuju za DNK ili nakon
metaboličkih transformacija (oksidacija i redukcija) pa SA struktura može da ukaže na
nastanak nekoliko toksičnih metabolita. Procena rizika na prisustvo GN u delu koji se odnosi
na profil nečistoća AS/GP je obavezan deo dokumentacije o kvalitetu leka koji se podnosi u
postupku registracije leka, kao i odobravanja kliničkih ispitivanja. U smernici ICHM7(2) su
date preporuke za identifikaciju, kategorizaciju, kvalifikaciju i kontrolnu strategiju
mutagenih nečistoća kako bi se ograničio potencijalni kancerogeni rizik. Prema ICHM7 se
vrši klasifikacija (klase 1-5) svih nečistoća na osnovu podataka o kancerogenosti i
bakterijskoj mutagenosti iz baza i naučne literature. Ako podaci nisu dostupni sprovodi se in
silico toksikološka procena (QSAR) i predviđa se bakterijska mutagenost sa dva nezavisna
modela. Ako jedan od modela pokaže SA strukture, radi se test povratne mutacije na
bakterijama (Ames test). Posebno se razmatraju visoko potentni mutageni kancerogeni
(aflatoksini, nitrozamini, alkil-azoksi jedinjenja).",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Genotoxic impurities in medicinal products – regulatory requirements, Genotoksične nečistoće u lekovima ‐ regulatorni zahtevi",
volume = "72",
number = "4 suplement",
pages = "S133-S134",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4476"
}
Čarapić, M., Nikolić, K.,& Agbaba, D.. (2022). Genotoxic impurities in medicinal products – regulatory requirements. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S133-S134.
https://hdl.handle.net/21.15107/rcub_farfar_4476
Čarapić M, Nikolić K, Agbaba D. Genotoxic impurities in medicinal products – regulatory requirements. in Arhiv za farmaciju. 2022;72(4 suplement):S133-S134.
https://hdl.handle.net/21.15107/rcub_farfar_4476 .
Čarapić, Marija, Nikolić, Katarina, Agbaba, Danica, "Genotoxic impurities in medicinal products – regulatory requirements" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S133-S134,
https://hdl.handle.net/21.15107/rcub_farfar_4476 .